**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 75583

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Prevalence and risk factors for** ***Candida* esophagitis among human immunodeficiency virus-negative individuals**

Chen YH *et al*. CE: Prevalence and risk factors

Yan-Hua Chen, Tzu-Ming Jao, Yow-Ling Shiue, I-Jung Feng, Ping-I Hsu

**Yan-Hua Chen,** Department of Internal Medicine, Kaohsiung Veterans General Hospital Pingtung Branch, Pingtung 91245, Taiwan

**Yan-Hua Chen, Yow-Ling Shiue,** Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan

**Yan-Hua Chen,** Department of Nursing, Meiho University, Pingtung 91202, Taiwan

**Tzu-Ming Jao,** Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813414, Taiwan

**Tzu-Ming Jao,** Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei 10617, Taiwan

**Yow-Ling Shiue, I-Jung Feng,** Institute for Precision Medicine, National Sun Yat-sen University, Kaohsiung 80424, Taiwan

**Ping-I Hsu,** Division of Gastroenterology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan 709204, Taiwan

**Author contributions:** All authors helped to perform the research; Chen YH and Hsu PI designed the study and drafted the manuscript; Chen YH, Jao TM, Shiue YL and Feng IJ collected the data; Chen YH, Jao TM, Shiue YL and Feng IJ performed statistical analyses; Chen YH, Jao TM, Shiue YL, Feng IJ and Hsu PI revised the manuscript critically for important intellectual content. All authors have read and approved the final manuscript.

**Supported by** the In-Hospital Research Project Funding of Kaohsiung Veterans General Hospital, No. VGHKS108-042; and An Nan Hospital, China Medical University, No. ANHRF109-38.

**Corresponding author: Ping-I Hsu, MD, Professor,** Division of Gastroenterology, Department of Internal Medicine, An Nan Hospital, China Medical University, No. 66 Sec. 2 Changhe Road, Annan District, Tainan 709204, Taiwan. williamhsup@yahoo.com.tw

**Received:** February 6, 2022

**Revised:** June 18, 2022

**Accepted:** July 27, 2022

**Published online:**

**Abstract**

BACKGROUND

*Candida* esophagitis (CE) is among the commonest esophageal infections and is known as an opportunistic fungal infection mostly affecting people living with the human immunodeficiency virus (HIV). However, some medical conditions might predispose HIV-negative individuals to esophageal candidiasis. The epidemiology and associated endoscopic findings of CE among people without HIV have rarely been reported.

AIM

To investigate the prevalence of CE among HIV-negative persons, and determine risk factors predicting CE.

METHODS

Between January 2015 and December 2018, all consecutive outpatients who underwent routine esophagogastroduodenoscopy as part of health check-ups at their own expense at the Health Check-up Center of the Kaohsiung Veterans General Hospital, Taiwan, were recruited in this study. Those with positive HIV serology results were excluded. Sociodemographic and clinical characteristics including age, gender, economic status, smoking history, alcohol consumption, tea and coffee consumption, underlying diseases, body fat percentage, body mass index, endoscopic findings, and *Helicobacter pylori* infection status were carefully reviewed. CE was confirmed by endoscopic biopsy and pathological assessment with hematoxylin and eosin and periodic acid-Schiff staining. To evaluate independent factors predicting the development of CE, we conducted a univariate analysis of clinical characteristics. The variables found to be significant *via* univariate analysis were subsequently included in a multivariable analysis of potential risk factors for CE development.

RESULTS

A total of 11802 participants were included in this study. Forty-seven (0.4%) were confirmed as having CE by pathological examination. Univariate analysis identified older age, the presence of chronic kidney disease, alcohol consumption, and steroid use (*P* = 0.023, < 0.001, 0.033, and 0.004, respectively) as significantly associated with CE. Multivariable analysis revealed older age [adjusted odds ratio (OR) = 1.027; 95%CI: 1.001-1.053; *P* = 0.045, chronic kidney disease (adjusted OR = 13.470; 95%CI: 4.574-39.673; *P* < 0.001), alcohol consumption (adjusted OR = 2.103; 95%CI: 1.151-3.844; *P* = 0.016), and steroid use (adjusted OR = 24.255; 95%CI: 5.343-110.115; *P* < 0.001) as independent risk factors for CE development. The presence of dysphagia was associated with severe CE (*P* = 0.021).

CONCLUSION

The prevalence of CE among HIV-negative persons was 0.4% in Taiwan. Independent risk factors for CE were older age, chronic kidney disease, alcohol consumption, and steroid use.

**Key Words:** *Candida* esophagitis; Prevalence; Risk factors; Human immunodeficiency virus

Chen YH, Jao TM, Shiue YL, Feng IJ, Hsu PI. Prevalence and risk factors for *Candida* esophagitis among human immunodeficiency virus-negative individuals. *World J Clin Cases* 2022; In press

**Core Tip:** *Candida* esophagitis (CE) is not only an opportunistic fungal infection affecting people living with the human immunodeficiency virus (HIV) but has also been identified in HIV-negative individuals. The prevalence of CE in Taiwan has reached 0.4% in general population, higher than previous reports. Significant risk factors include older age, chronic kidney disease, alcohol consumption, and steroid use. It is among the etiologies causing dysphagia in the general population, and esophagogastroduodenoscopy combined with histopathological examination are essential for accurate diagnosis.

**INTRODUCTION**

*Candida* esophagitis (CE) is a fungal infection of the esophagus caused by *Candida* species. It is one of the most common esophageal infections and is known as an opportunistic infection associated with human immunodeficiency virus (HIV) infection[1-5]. *Candida* *albicans* is the causative agent in most cases. Infections caused by other species such as *C. glabrata*, *C. dubliniensis*, *C. tropicalis*, C. *stellatoidea* and *C. krusei* have been reported[6,7]. In HIV-negative individuals, the prevalence of CE ranges from 0.3%-10.5%[8-11].

Some medical conditions and treatments, including the presence of malignancies, diabetes mellitus, steroids, radiation therapy, antimicrobial therapy, liver cirrhosis, acid suppression therapy, and dentures, have been associated with CE development[9,12,13]. Upper endoscopy is a sensitive and reliable method for diagnosing CE[14]. The typical endoscopic findings of CE are elevated white plaques coating the esophageal mucosa with either a nodular, linear, or confluent pattern. An endoscopic severity grading for CE has been proposed by Kodsi *et al*[15], Asayama *et al*[16] and Takahashi *et al*[17].

Currently, the prevalence of CE among HIV-negative individuals remains unknown in Taiwan. We aimed to investigate the prevalence of CE among HIV-negative individuals in Taiwan and determine independent risk factors for CE development in the general population.

**MATERIALS AND METHODS**

***Patients***

Between January 2015 and December 2018, all consecutive outpatients who underwent routine esophagogastroduodenoscopy (EGD) as part of health check-ups at their own expense at the Health Check-up Center of the Kaohsiung Veterans General Hospital, Taiwan, were recruited in this study. Most of these individuals were physically healthy without medical illness or signs of immunodeficiency and underwent health check-ups to rule out physical disorders, particularly malignancy. Other participants either had routine physical check-ups arranged by their employers or sought medical consultations to evaluate physical symptoms. An HIV serologic test was performed in 81% of the population. The exclusion criteria were: (1) Age < 20 years; (2) Refused biopsy for suspicious gastrointestinal tract lesions; and (3) A positive HIV serology result.

***Questionnaire***

As a routine practice at our physical examination center, every outpatient was instructed to fill out a questionnaire detailing their personal history, demographic data, medical history, as well as their history of smoking, alcohol consumption, and coffee and tea consumption. The questionnaire was designed with a mainly dichotomous manner, and the questions were divided in detail according to different functional systems of the human body. The questionnaire also captured self-reported gastrointestinal discomfort or symptoms, including acid reflux symptoms, epigastric pain, dysphagia, odynophagia, and dyspepsia.

***Study design***

Clinical data including personal information from the questionnaire, laboratory data, body weight, body mass index (BMI), body fat percentage, endoscopic findings, and histopathologic findings were collected by retrospective chart review. The endoscopy devices used for examinations from January 2015 through August 2015 were the GIF-XP260N, GIF-XQ260, GIF-Q260, and GIF-H260Z systems (Tokyo, Japan). New endoscopy systems, the GIF-H290Z and GIF-HQ290, were introduced to our department and used for endoscopic examinations from September 2015 onward. All endoscopic examinations throughout the entire study period were performed by five experienced endoscopists. Most of the endoscopic procedures were performed under conscious sedation with the administration of intravenous sedative agents by anesthesiologists. Some patients did not undergo conscious sedation because of advanced age, high risk of anesthesia complications due to underlying medical conditions, or personal reasons. If a participant underwent more than one endoscopic examination during the study period, only the results of the first examination were included in the analysis. CE was suspected when we endoscopically identified white plaques coating the esophageal mucosa that could not be washed away[18]. The endoscopic CE severity was graded according to the classification proposed by Kodsi *et al*[15]. The diagnosis was confirmed by endoscopic biopsy for histopathologic assessment with hematoxylin and eosin and periodic acid-Schiff staining.

***Statistical analysis***

The primary endpoint was the presence of histopathologically-confirmed CE. To identify risk factors for CE, we conducted univariate analysis with the chi-square test or Fisher’s exact test for categorical variables and two sample t test for continuous variables, to individually investigate the associations between 29 clinical variables and the presence of CE. These variables included age; gender; smoking history; alcohol consumption history; coffee, tea, and betel nuts use; underlying disease status; surgical history; systemic steroid use; *Helicobacter pylori* infection status; waist circumference (normal: < 90 cm for males and < 80 cm for females; obese: ≥ 90 cm for males and ≥ 80 cm for females); body fat percentage (normal: < 25% for males and < 30% for females; obese: ≥ 25% for males and ≥ 30% for females); BMI (normal: < 24; overweight: 24 ≤ BMI < 27; obese: ≥ 27); and endoscopic findings. The variables found to be statistically significant in the univariate analysis were subsequently assessed by multivariable logistic regression analysis to identify independent factors predicting CE. All statistical analyses were performed using the SPSS for Windows, version 12.0 (SPSS Inc., Chicago, IL, United States). *P*-values less than 0.05 were considered statistically significant. The statistical methods in this study were reviewed by Dr. I-Jung Feng, Associate Professor of Biostatistics in National Sun Yat-sen University, Kaohsiung City, Taiwan.

**RESULTS**

***Participant characteristics and endoscopic findings***

During the study period, a total of 11805 participants were enrolled. Most of these individuals (*n* = 7968, 67.5%) were physically healthy and underwent their health check-ups to rule out physical disorders, particularly malignancies. The remaining individuals either underwent employment-related check-ups (*n* = 2691, 22.8%) or had sought medical consultations to evaluate physical symptoms (*n* = 1146, 9.7%). Of these, we excluded two participants who refused biopsy sample collection and one with a positive HIV serology result. Finally, the data of 11802 individuals (mean age, 51.29 ± 11.58 years; 55.7% male) were included in the analyses.

Endoscopically suspected CE was observed in 71 (0.6%) individuals, and 47 participants were confirmed to have CE *via* biopsy examination. Therefore, the overall prevalence of CE was 0.4%. The histopathologic diagnoses of the remaining 24 participants were normal esophageal mucosa (*n* = 3), chronic esophagitis (*n* = 18), and glycogenic acanthosis (*n* = 3). No dysplasia or adenocarcinoma was detected. Among the included 11802 individuals, a total of 9560 participants received HIV serology testing, and the results were negative. The prevalence of CE in the participants with negative results of HIV serology was 0.5%.

***Univariate analysis of clinical characteristics associated with CE***

Table 1 shows the clinical characteristics of the subjects with and without CE. The mean age was significantly higher among individuals with CE than among those without CE. Alcohol consumption, chronic kidney disease (CKD), and steroid use were more common among participants with CE. Although men and obese individuals (defined by a high body fat percentage) were more likely to have CE than women and participants with normal body fat percentages, respectively, these differences were not statistically significant.

***Multivariable analysis of independent factors predicting the development of CE***

Multivariable analysis revealed older age [adjusted odds ratio (OR) = 1.027; 95%CI: 1.001-1.053; *P* = 0.045], CKD (adjusted OR = 13.470; 95%CI: 4.574-39.673; *P* < 0.001), steroid use (adjusted OR = 24.255; 95%CI: 5.343-110.115; *P* < 0.001), and alcohol consumption (adjusted OR = 2.103; 95%CI: 1.151-3.844; *P* = 0.016) as significant risk factors for CE development (Table 2).

***Clinical symptoms predicting endoscopic severity***

The endoscopic appearance of CE was classified as grade I to grade IV according to the Kodsi system[15]. Table 3 summarizes the association between the endoscopic severity of CE and clinical symptoms. Most of the participants were classified as grade II (*n* = 29). Of the 47 participants with histopathologically-confirmed CE, seven had chest pain, three had abdominal pain, and one had dysphagia. None of the patients complained of globus, acid reflux, or odynophagia. The presence of dysphagia was associated with severe CE (*P* = 0.021).

**DISCUSSION**

CE is the most common opportunistic gastrointestinal disorder among people living with HIV, and a low CD4+ cell count (< 200 cells/mL) is one of the most important risk factors for CE in this population[19]. However, in the HIV-negative population, CE is occasionally identified accidentally during EGD for other indications. In this study, 47 otherwise healthy subjects undergoing routine health check-ups in Taiwan were confirmed to have CE, reflecting an overall prevalence of 0.4%. Our study also demonstrated older age, CKD, steroid use, and alcohol consumption as independent risk factors predicting the presence of CE.

The previously reported prevalence of CE in HIV-negative populations ranges from 0.3%-10.5%; these rates have tended to increase over time[17]. However, the prevalence of CE in the general population is rarely discussed. Choi *et al*[8] conducted a retrospective study from July 2005 through April 2011 to evaluate the prevalence of incidentally identified CE among healthy individuals in Korea, diagnosed endoscopically or histologically; they found a prevalence of 0.32%. Another retrospective study conducted in Korea by Kim *et al*[9] revealed a 0.35% prevalence of histology proven CE in a health check-up population. Recently, Ou *et al*[13] determined a prevalence of 0.39% among patients undergoing EGD for various medical conditions in Taipei, Taiwan. However, most of their patients with CE were diagnosed by endoscopic findings and not confirmed histopathologically. In our study, all CE diagnoses were confirmed by histopathologic examination. The results estimate the prevalence of CE in the Taiwanese general population to be 0.40%. We also identified older age, steroid use, alcohol consumption, and CKD as independent risk factors for CE development.

*Candida albicans* commonly colonizes the human gastrointestinal tract, with a variety of adhesins facilitating attachment to epithelial and endothelial surfaces[20]. Whether or not mucocutaneous invasion or systemic infection occurs depends on host and fungal factors[21]. Oral or aerosolized corticotherapy is a well-known risk factor associated with CE[22-24]. The prevalence of CE among inhaled corticosteroid users has been reported to be as high as 37%[25].

We are not the first to report alcohol consumption as an independent risk factor for CE development. Choi *et al*[8] and Zillessen *et al*[26] also identified alcohol consumption as a significant predisposing factor for CE. Recently, a retrospective study conducted at the endoscopy unit of a tertiary hospital in Mwanza, Tanzania, by Mushi *et al*[27] also identified that individuals with a history of alcohol consumption were at high risk of developing CE. According to previous reports, the amount of gastric acid output may be influenced by different alcohol concentrations; beverages with low ethanol content, such as beer and wine, are stimulants of gastric acid secretion, while beverages with higher ethanol concentrations, such as spirits, do not stimulate and even may decrease gastric acid secretion[28,29]. Moreover, the stomach's adaptive capacity may change its response to alcohol in association with chronic alcoholism. Atrophic gastritis and superficial gastritis, with or without associated hyposecretion of gastric acid or achlorhydria, are more often associated with chronic alcoholism[28]. In addition, the parietal cells, which are responsible for acid secretion, decrease in number with increasing alcohol exposure[29]. Given that acid suppression therapy probably facilitating colonization of the esophagus by oral bacteria and yeast due to elevated gastric pH may contribute to the development of CE, heavy alcohol consumption may also increase the risk of CE *via* the same mechanism[28,30-32].

In the present study, older age was another independent risk factor associated with CE development. This finding was consistent with previous findings by Takahashi *et al*[17], who demonstrated advanced age as a risk factor for CE among HIV-negative patients[20]. Indeed, the aging process may attenuate the host’s ability to mount a robust or effective immune response. The underlying mechanism of impaired immunity may be associated with defects in hematopoietic bone marrow and peripheral lymphocyte migration, maturation, and function[33].

The present study also revealed CKD as an independent risk factor for CE development. This important finding has rarely been reported. Thorman *et al*[34] reported that oral fungal infection was significantly more prevalent among patients with end-stage renal disease (ESRD). In addition, lymphocyte numbers and the CD4/CD8 ratio are diminished in patients with ESRD. In fact, both the quantity and quality of T-cell activation are impaired in the context of chronic renal failure[35]. Furthermore, cellular mechanisms are essential in host responses to fungal infections and candidiasis at the gastrointestinal surface. Dysfunction of T-lymphocytes and a reduction in their number are typically observed in patients with mycotic diseases. Reductions in T-lymphocyte number and in the ratio of T-helper to T-suppressor cells are of critical importance for explaining diminished IgA production and enhanced adhesion of fungal cells to the surface of host cells, as well as for facilitating the intrusion of fungi throughout the skin and mucous membranes[20]. Therefore, it is reasonable to expect CKD as a risk factor for CE.

Common symptoms associated with CE include dysphagia, odynophagia, retrosternal chest pain, epigastric pain, and acid reflux symptoms[16,22]. A cross-sectional study conducted by Takahashi *et al*[10] found dysphagia and odynophagia as the only two symptoms predicting CE among individuals without HIV. In our study, the presenting symptoms among participants with CE were chest pain (*n* = 7, 14.9%), abdominal pain (*n* = 3, 6.4%) and dysphagia (*n* = 1, 2.1%), similar to the findings mentioned above. However, none of these symptoms were significantly associated with CE according to the multivariable analysis.

The association between clinical symptoms and the endoscopic severity of CE graded by Kodsi’s classification has been investigated before. Asayama *et al*[16] reported that the presence of odynophagia was significantly associated with grade III and grade IV CE. In our study, none of the participants with CE presented with odynophagia. Although none of the patients with grade I to grade III CE presented with dysphagia, dysphagia was a presenting complaint in the one patient with grade IV CE.

This study has several limitations. First, its retrospective observational design means that it was subject to confounding by unmeasured variables. Second, in real-world clinical practice, some situational factors can influence the CE detection rate, such as the foregoing of endoscopic biopsy examination because of overlooked low-grade CE or misdiagnoses of CE as foreign body reactions or glycogenic acanthosis. Third, there were relatively few CE cases, making it difficult to definitively confirm associations between clinical symptoms and the endoscopic severity of CE.

**CONCLUSION**

In conclusion, the prevalence of CE among HIV-negative participants in this single-center cohort in Taiwan was 0.4% from 2015 through 2018. Older age, CKD, alcohol consumption, and steroid use were independent risk factors for CE development.

**ARTICLE HIGHLIGHTS**

***Research background***

*Candida* esophagitis (CE) is an opportunistic esophageal fungal infection mostly affecting human immunodeficiency virus (HIV)-positive people. However, some HIV-negative individuals are prone to esophageal candidiasis under certain medical conditions.

***Research motivation***

The definite diagnosis of CE relies on both endoscopic and histopathological findings. However, the epidemiology of CE diagnosed with strict histopathological confirmation among the general population without HIV in Taiwan has rarely been reported.

***Research objectives***

To update the prevalence of CE among HIV-negative persons, and identify independent risk factors predicting CE in Taiwan.

***Research methods***

HIV-negative outpatients who underwent routine esophagogastroduodenoscopy at the Health Check-up Center of the Kaohsiung Veterans General Hospital, Taiwan, between January 2015 and December 2018 were recruited. Sociodemographic status, clinical characteristics, and endoscopic findings were carefully reviewed. CE was confirmed by endoscopic biopsy and pathological assessment. A univariate analysis of clinical characteristics was conducted to evaluate independent factors predicting CE. Significant variables found *via* univariate analysis were subsequently included in a multivariable analysis of potential risk factors for CE development.

***Research results***

A total of 11802 participants were included in this study. The prevalence of CE confirmed by pathological examination was 0.4%. Multivariable analysis revealed older age [adjusted odds ratio (OR) = 1.027; 95%CI: 1.001-1.053; *P* = 0.045], chronic kidney disease (adjusted OR = 13.470; 95%CI: 4.574-39.673; *P* < 0.001), alcohol consumption (adjusted OR = 2.103; 95%CI: 1.151-3.844; *P* = 0.016), and steroid use (adjusted OR = 24.255; 95%CI: 5.343-110.115; *P* < 0.001) as independent risk factors for CE development.

***Research conclusions***

The prevalence of CE among HIV-negative population in Taiwan has reached 0.4%. Older age, chronic kidney disease, alcohol consumption, and steroid use were independent risk factors for CE.

***Research perspectives***

CE is not an uncommon esophageal disease among the HIV-negative population in Taiwan. Chronic kidney disease was an independent risk factor for the development of CE, which was a unique finding in our study.

**REFERENCES**

1 **Eras P**, Goldstein MJ, Sherlock P. Candida infection of the gastrointestinal tract. *Medicine (Baltimore)* 1972; **51**: 367-379 [PMID: 4560040 DOI: 10.1097/00005792-197209000-00002]

2 **Young JA**, Elias E. Gastro-oesophageal candidiasis: diagnosis by brush cytology. *J Clin Pathol* 1985; **38**: 293-296 [PMID: 3973054 DOI: 10.1136/jcp.38.3.293]

3 **Wheeler RR**, Peacock JE Jr, Cruz JM, Richter JE. Esophagitis in the immunocompromised host: role of esophagoscopy in diagnosis. *Rev Infect Dis* 1987; 9: 88-96 [PMID: 3823720 DOI: 10.1093/clinids/9.1.88]

4 **López-Dupla M**, Mora Sanz P, Pintado García V, Valencia Ortega E, Uriol PL, Khamashta MA, Aguado AG. Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. *Am J Gastroenterol* 1992; **87**: 1771-1776 [PMID: 1449139]

5 **Mönkemüller KE**, Lazenby AJ, Lee DH, Loudon R, Wilcox CM. Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy. *Dig Dis Sci* 2005; **50**: 230-234 [PMID: 15745077 DOI: 10.1007/s10620-005-1587-z]

6 **Bonacini M**, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. *Arch Intern Med* 1991; **151**: 1567-1572 [PMID: 1651690]

7 **Kliemann DA**, Pasqualotto AC, Falavigna M, Giaretta T, Severo LC. Candida esophagitis: species distribution and risk factors for infection. *Rev Inst Med Trop Sao Paulo* 2008; **50**: 261-263 [PMID: 18949340 DOI: 10.1590/s0036-46652008000500002]

8 **Choi JH**, Lee CG, Lim YJ, Kang HW, Lim CY, Choi JS. Prevalence and risk factors of esophageal candidiasis in healthy individuals: a single center experience in Korea. *Yonsei Med J* 2013; **54**: 160-165 [PMID: 23225813 DOI: 10.3349/ymj.2013.54.1.160]

9 **Kim KY**, Jang JY, Kim JW, Shim JJ, Lee CK, Dong SH, Kim HJ, Kim BH, Chang YW. Acid suppression therapy as a risk factor for Candida esophagitis. *Dig Dis Sci* 2013; **58**: 1282-1286 [PMID: 23306845 DOI: 10.1007/s10620-012-2520-x]

10 **Takahashi Y**, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, Sekine K, Okubo H, Watanabe K, Sakurai T, Yokoi C, Mimori A, Oka S, Uemura N, Akiyama J. Upper Gastrointestinal Symptoms Predictive of Candida Esophagitis and Erosive Esophagitis in HIV and Non-HIV Patients: An Endoscopy-Based Cross-Sectional Study of 6011 Patients. *Medicine (Baltimore)* 2015; **94**: e2138 [PMID: 26632738 DOI: 10.1097/MD.0000000000002138]

11 **Gupta KL**, Ghosh AK, Kochhar R, Jha V, Chakrabarti A, Sakhuja V. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. *Am J Gastroenterol* 1994; **89**: 1062-1065 [PMID: 8017366]

12 **Kauffman CA,** Pappas PG, Sobel JD, Dismukes WE. Essentials of Clinical Mycology. New York: Springer, 2011

13 **Ou TM,** Huang HH, Hsieh TY, Chang WK, Chu HC, Hsu CH, Shih YL, Huang TY, Chen PJ, Lin HH. Liver cirrhosis as a predisposing factor for esophageal candidiasis. *Adv* *Dig Med* 2014; **1**: 86-91 [DOI: 10.1016/j.aidm.2013.09.005]

14 **Redah D**, Konutse AY, Agbo K, Dogbey EH, Napo-Koura G, Tchangai-Kao ST, Prince-David M, Amedegnato DM, Agbetra A. [Is endoscopic diagnosis of Candida albicans esophagitis reliable? Correlations with pathology and mycology]. *Gastroenterol Clin Biol* 2001; **25**: 161-163 [PMID: 11319441]

15 **Kodsi BE**, Wickremesinghe C, Kozinn PJ, Iswara K, Goldberg PK. Candida esophagitis: a prospective study of 27 cases. *Gastroenterology* 1976; **71**: 715-719 [PMID: 964563]

16 **Asayama N**, Nagata N, Shimbo T, Nishimura S, Igari T, Akiyama J, Ohmagari N, Hamada Y, Nishijima T, Yazaki H, Teruya K, Oka S, Uemura N. Relationship between clinical factors and severity of esophageal candidiasis according to Kodsi's classification. *Dis Esophagus* 2014; **27**: 214-219 [PMID: 23826847 DOI: 10.1111/dote.12102]

17 **Takahashi Y**, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, Sekine K, Okubo H, Watanabe K, Sakurai T, Yokoi C, Kobayakawa M, Yazaki H, Teruya K, Gatanaga H, Kikuchi Y, Mine S, Igari T, Takahashi Y, Mimori A, Oka S, Akiyama J, Uemura N. Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients. *PLoS One* 2015; **10**: e0133589 [PMID: 26208220 DOI: 10.1371/journal.pone.0133589]

18 **Baehr PH**, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. *Gastroenterology* 1994; **106**: 509-532 [PMID: 7980741 DOI: 10.1016/0016-5085(94)90613-0]

19 **Nishimura S**, Nagata N, Shimbo T, Asayama N, Akiyama J, Ohmagari N, Yazaki H, Oka S, Uemura N. Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy. *PLoS One* 2013; **8**: e58217 [PMID: 23555571 DOI: 10.1371/journal.pone.0058217]

20 **Shoham S**, Levitz SM. The immune response to fungal infections. *Br J Haematol* 2005; **129**: 569-582 [PMID: 15916679 DOI: 10.1111/j.1365-2141.2005.05397.x]

21 **Cole GT**, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. *Clin Infect Dis* 1996; **22 Suppl 2**: S73-S88 [PMID: 8722833 DOI: 10.1093/clinids/22.supplement\_2.s73]

22 **Ortuño Cortés JA**, Tovar Martínez A, Ruiz Riquelme J, García García A. Esophageal candidiasis in HIV-negative patients. *Rev Esp Enferm Dig* 1997; **89**: 503-510 [PMID: 9265836]

23 **Simon MR**, Houser WL, Smith KA, Long PM. Esophageal candidiasis as a complication of inhaled corticosteroids. *Ann Allergy Asthma Immunol* 1997; **79**: 333-338 [PMID: 9357379 DOI: 10.1016/S1081-1206(10)63024-4]

24 **Chocarro Martínez A**, Galindo Tobal F, Ruiz-Irastorza G, González López A, Alvarez Navia F, Ochoa Sangrador C, Martín Arribas MI. Risk factors for esophageal candidiasis. *Eur J Clin Microbiol Infect Dis* 2000; **19**: 96-100 [PMID: 10746494 DOI: 10.1007/s100960050437]

25 **Kanda N**, Yasuba H, Takahashi T, Mizuhara Y, Yamazaki S, Imada Y, Izumi Y, Kobayashi Y, Yamashita K, Kita H, Tamada T, Chiba T. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. *Am J Gastroenterol* 2003; **98**: 2146-2148 [PMID: 14572559 DOI: 10.1111/j.1572-0241.2003.07626.x]

26 **Zillessen E**, Palme W, Feichter GE. [Candidiasis of the esophagus. Prospective study of incidence, type of complaints and predisposing factors]. *Dtsch Med Wochenschr* 1986; **111**: 1200-1207 [PMID: 3732073 DOI: 10.1055/s-2008-1068607]

27 **Mushi MF**, Ngeta N, Mirambo MM, Mshana SE. Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. *Afr Health Sci* 2018; **18**: 66-71 [PMID: 29977259 DOI: 10.4314/ahs.v18i1.10]

28 **Chari S**, Teyssen S, Singer MV. Alcohol and gastric acid secretion in humans. *Gut* 1993; **34**: 843-847 [PMID: 8314520 DOI: 10.1136/gut.34.6.843]

29 **Adegor EC,** Ojieh AE, Eghworo O, Ewhre LO, Daubry TME, Onyekpe CU. Evaluation of Long Term Alcohol Consumption on Gastric Acid Secretion and the Histomorphometry of the Stomach in Adult Male Wistar Rats. *UK J* *Pharm Biosci* 2016; **4**: 7 [DOI: 10.20510/ukjpb/4/i5/118027]

30 **Singer MV**, Leffmann C, Eysselein VE, Calden H, Goebell H. Action of ethanol and some alcoholic beverages on gastric acid secretion and release of gastrin in humans. *Gastroenterology* 1987; **93**: 1247-1254 [PMID: 3678743 DOI: 10.1016/0016-5085(87)90252-6]

31 **Kochhar R**, Talwar P, Singh S, Mehta SK. Invasive candidiasis following cimetidine therapy. *Am J Gastroenterol* 1988; **83**: 102-103 [PMID: 3337055]

32 **Karmeli Y**, Stalnikowitz R, Eliakim R, Rahav G. Conventional dose of omeprazole alters gastric flora. *Dig Dis Sci* 1995; **40**: 2070-2073 [PMID: 7555466 DOI: 10.1007/BF02208680]

33 **Gruver AL**, Hudson LL, Sempowski GD. Immunosenescence of ageing. *J Pathol* 2007; **211**: 144-156 [PMID: 17200946 DOI: 10.1002/path.2104]

34 **Thorman R**, Neovius M, Hylander B. Prevalence and early detection of oral fungal infection: a cross-sectional controlled study in a group of Swedish end-stage renal disease patients. *Scand J Urol Nephrol* 2009; **43**: 325-330 [PMID: 19363743 DOI: 10.1080/00365590902836492]

35 **Girndt M**, Sester U, Sester M, Kaul H, Köhler H. Impaired cellular immune function in patients with end-stage renal failure. *Nephrol Dial Transplant* 1999; **14**: 2807-2810 [PMID: 10570074 DOI: 10.1093/ndt/14.12.2807]

**Footnotes**

**Institutional review board statement:** This study was reviewed andapproved by the Institutional Review Board of Kaohsiung Veterans General Hospital (VGHKS18-CT10-11).

**Informed consent statement:** Patients were not required to give informed consent to the study as the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** The Digestive Endoscopy Society of Taiwan, No. 108019.

**Peer-review started:** February 6, 2022

**First decision:** May 29, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Taiwan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Hung K, United States; Ravishankar PL, India; Sawada A, Japan **S-Editor:** Zhang H **L-Editor:** Webster JR **P-Editor:** Zhang H

**Table 1 Univariate analysis of clinical characteristics associated with *Candida* esophagitis**

|  |  |  |
| --- | --- | --- |
| **Characteristics**  | ***Candida* esophagitis (%)** | ***P* value** |
| **Yes (*n* = 47)** | **No (*n* = 11755)** |
| Age (yr) (mean ± SD) | 55.13 ± 11.73 | 51.27 ± 11.58 | 0.023 |
| Male gender | 32 (68.1) | 6541 (55.6) | 0.087 |
| Smoking | 9 (19.1) | 1979 (16.8) | 0.672 |
| Consumption of alcohol  | 30 (63.8) | 5674 (48.3) | 0.033 |
| Consumption of betel nuts | 3 (6.4) | 400 (3.4) | 0.216 |
| Underlying disease |  |  |  |
| Cardiovascular disease | 5 (10.6) | 1520 (12.9) | 0.640 |
| Pulmonary disease | 3 (6.4) | 542 (4.6) | 0.478 |
| Diabetes mellitus | 4 (8.5) | 845 (7.2) | 0.579 |
| Hepatitis | 6 (12.8) | 975 (8.3) | 0.281 |
| Malignancy | 0 (0) | 224 (1.9) | 1.000 |
| Hyperlipidemia | 6 (12.8) | 1376 (11.7) | 0.821 |
| Chronic kidney disease | 4 (8.5) | 70 (0.6) | < 0.001 |
| Steroid use | 2 (4.3) | 21 (0.2) | 0.004 |
| Previous gastric surgery | 0 (0) | 3 (< 0.1) | 1.000 |
| Symptoms |  |  |  |
| Acid reflux | 0 (0) | 344 (2.9) | 0.648 |
| Chest pain | 7 (14.9) | 1549 (13.2) | 0.729 |
| Nausea/vomiting | 0 (0) | 200 (1.7) | 1.000 |
| Abdominal pain | 3 (6.4) | 1264 (10.8) | 0.334 |
| Dysphagia | 1 (2.1) | 134 (1.1) | 0.525 |
| Odynophagia | 0 (0) | 7 (0.1) | 0.867 |
| Globus | 0 (0) | 25 (0.2) | 1.000 |
| Waist |  |  | 0.182 |
| Normal (< 90 cm for males, < 80 cm for females) | 26 (55.3) | 7600 (64.7) |  |
| Obese (≥ 90 cm for males, ≥ 80 cm for females) | 21 (44.7) | 4155 (35.3) |  |
| Body fat percentage |  |  | 0.081 |
| Normal (< 25% for males, < 30% for females) | 28 (59.6) | 8347 (71.1) |  |
| Obese (≥ 25% for males, ≥ 30% for females) | 19 (40.4) | 3387 (28.9) |  |
| BMI |  |  | 0.463 |
| Normal (BMI < 24) | 22 (46.8) | 6523 (55.5) |  |
| Overweight (24 ≤ BMI < 27) | 15 (31.9) | 3293 (28.0) |  |
| Obese (27 ≥ BMI) | 10 (21.3) | 1939 (16.5) |  |
| *Helicobacter pylor*i infection | 9 (19.1) | 2047 (17.4) | 0.754 |
| Endoscopic findings |  |  |  |
| Reflux esophagitis | 7 (14.9) | 2940 (25.0) | 0.110 |
| Hiatal hernia | 20 (42.6) | 5302 (45.1) | 0.726 |
| Gastric ulcer | 23 (48.9) | 4896 (41.7) | 0.312 |
| Duodenal ulcer | 2 (4.3) | 850 (7.2) | 0.580 |
| Gastric and duodenal ulcer | 23 (48.9) | 5179 (44.1) | 0.501 |
| ESEM | 5 (10.6) | 1277 (10.9) | 0.961 |
| Barrett's esophagus | 1 (2.1) | 283 (2.4) | 1.000 |

BMI: Body mass index; ESEM: Endoscopically suspected esophageal metaplasia.

**Table 2 Multivariable analysis of risk factors predicting *Candida* esophagitis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Clinical factor**  | **Coefficient**  | **Standard error**  | **Odds ratio (95%CI)**  | ***P* value** |
| Age | 0.026 | 0.013 | 1.027 (1.001-1.053) | 0.045 |
| Chronic kidney disease | 2.600 | 0.551 | 13.470 (4.574-39.673) | < 0.001 |
| Steroid use | 3.189 | 0.772 | 24.255 (5.343-110.115) | < 0.001 |
| Alcohol consumption | 0.743 | 0.308 | 2.103 (1.151-3.844) | 0.016 |

**Table 3 The relationship between endoscopic severity of *Candida* esophagitis and clinical symptoms**

|  |  |  |
| --- | --- | --- |
| **Symptoms** | **Severity (%)** | ***P* value** |
| **Grade 1 (*n* = 11)** | **Grade 2 (*n* = 29)** | **Grade 3 (*n* = 6)** | **Grade 4 (*n* = 1)** |
| Chest pain | 3 (27.3) | 4 (13.8) | 0 (0) | 0 (0) | 0.564 |
| Abdominal pain | 1 (9.1) | 2 (6.9) | 0 (0) | 0 (0) | 1.000 |
| Dysphagia | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0.021 |
| Globus | 0 (0) | 0 (0) | 0 (0) | 0 (0) | N/A |
| Acid reflux | 0 (0) | 0 (0) | 0 (0) | 0 (0) | N/A |
| Odynophagia | 0 (0) | 0 (0) | 0 (0) | 0 (0) | N/A |

N/A: Not applicable.